In particular, a clinical PET study using [11C] verapamil as a marker of P-gp function provided evidence of increased P-gp activity in long-term treated patients [56], which can explain treatment resistance in MDD, as P-gp acts as an efflux pump, limiting antidepressant accumulation in the CNS. The gene discussed is PGP; the disease is major depressive disorder.